Oct. 29, 2026 -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the first patient dosing has been completed in a multi-center, randomized, controlled, and open-label phase 3 clinical study evaluating the efficacy and safety of the company’s product, recombinant humanized anti-PD-1/VEGF bispecific antibody (cod

AdipoPharma Advances PATAS into Phase 1b Clinical Trial in Patients with Type 2 Diabetes First participants with Type 2 diabetes dosed in multiple ascending dose (MAD) study evaluating AdipoPharma’s first-in-class insulin sensitizer Advancement follows successful completion of the single ascending dose (SAD) phase, where PATAS was well tolerated with no serious adverse events Oct. 27, 2026 -- AdipoPharma, a clinical-stage biotechnology company developing therapies that target adipocyte dysfunc

Phase 3 TEMPLE study evaluated the tolerability, safety and efficacy of atogepant (QULIPTA®) compared with topiramate for the preventive treatment of migraine in adults with a history of four or more migraine days per month.1 Atogepant (QULIPTA®) demonstrated superior efficacy across key clinical and functional outcomes, including reductions in monthly migraine days and improvements in headache-related disability, daily functioning and cognitive function.1 25% of Canadian households are impacted

Egetis Therapeutics Announces U.S. Launch of EMCITATE® for Patients with MCT8 Deficiency EMCITATE is the first and only FDA-approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency in the United States Egetis RareLink™, the dedicated patient support program, provides access assistance, education and care coordination in partnership with PANTHERx® Rare Pharmacy Sept. 27, 2026 – Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockho

Oct. 26, 2026 -- OncoHost, a technology company transforming the approach to predictive precision diagnostics for improved patient outcomes, today announced new research that was presented at the European Society for Medical Oncology (ESMO) 2026 Congress, taking place October 23–27 in Madrid, Spain. The study, "Plasma Proteomics Reveals the Biological Landscape of Tyrosine Kinase Inhibitors (TKI) Sensitivity in Metastatic Renal Cell Carcinoma," examines the biological basis of a model that uses

Oct. 27, 2026 -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase III clinical trial evaluating zemprocitinib, an investigational, selective, second-generation oral Janus kinase 1 (JAK1) inhibitor, in adult patients with moderate-to-severe active rheumatoid arthritis (RA) who had experienced inadequate response or intolerance

TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability pro of systemic administration in an outpatient setting With median follow-up of 12.7 months, objective response rate (ORR) for the squamous cohort was 72% and disease control rate (DCR) was 100%, with a median duration of response of 12.9 months and multiple participants continuing in active

Median overall survival of 12 months with RBS2418 monotherapy in subjects with heavily pretreated tumors that express ENPP1 and cGAS proteins (TME-EG+ phenotype), versus 4.2 months in subjects whose tumors do not (median 3 prior systemic therapies; p=0.0022) Median overall survival of 14 months in heavily pretreated TME-EG+ late-line metastatic colorectal cancer (mCRC, median 4 prior systemic therapies), including subjects with liver metastases Well tolerated, with no treatment-related serious a

With RAS-targeted therapies gaining ground in pancreatic cancer, Incyte is advancing its own contender. On Monday, the company shared what it called "encouraging" early data for its experimental KRAS G12D inhibitor INCB161734, along with two new partnerships, including one with Bristol Myers Squibb, to test the drug in separate combos against the disease. Phase I findings, presented at the European Society for Medical Oncology (ESMO) congress, showed the oral drug produced an objective response

Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Krascendo 1 study1,2 At the time of primary analysis, divarasib achieved a median overall survival of approximately 18 months, compared to 12 months for sotorasib or adagrasib1,2 No new safety signals were observed with divarasib; the most common treatment-related adverse events were mainly